Frontline Management of High-Risk Multiple Myeloma or Plasmacytoma With BCMA and GPRC5D Combination CAR-T Cell Therapy
Status: Not_yet_recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
The aim of this clinical trial is to assess the feasibility, safety, and efficacy of CAR-T cell therapy targeting multiple cancer cell antigens in high-risk multiple myeloma or plasmacytoma as part of a frontline treatment regimen for patients. Another goal of the study is to learn more about the persistence and function of these CAR-T cells in the body.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• Male and female subjects with multiple myeloma or plasmacytoma
• Strictly complete remission (sCR) is a treatment goal
• Expected survival \> 12 weeks
• After prior auto-SCT is eligible regardless of other prior therapies
• Adequate venous access for apheresis, and no other contraindications for leukapheresis
• Voluntary informed consent is given and commitment to continued follow-up
Locations
Other Locations
China
Shenzhen Geno-immune Medical Institute
Shenzhen
Contact Information
Primary
Lung-Ji Chang, ph.D
c@szgimi.org
+86 0755-86573763
Time Frame
Start Date: 2026-12-31
Completion Date: 2028-12-31
Participants
Target number of participants: 20
Treatments
Experimental: CAR-T cells to treat MM
Related Therapeutic Areas
Sponsors
Leads: Shenzhen Geno-Immune Medical Institute